The aim of this study was to compare the effects of single-dose methotrexate (MTX) and salpingectomy on ovarian reserve in women with ectopic pregnancy in the late post-treatment period. A total of 181 patients were included in the study; 56 of them received a single-dose of MTX, 45 of them had undergone salpingectomy treatment for ectopic pregnancy in the previous 12-18 months, and 80 healthy women constituted an age-matched control group. The anti-müllerian hormone (AMH), follicle stimulating hormone (FSH) and oestrogen (E) levels, as well as antral follicle counts (AFC) of the patients were evaluated. The average age was similar in both groups (p = 0.094) and there was no statistically significant difference in the smoking status of the patients (p = 0.949). None of the three groups displayed a significant difference in terms of AFC (p = 0.528), AMH (p = 0.147), FSH (p = 0.393) and E levels (p = 0.117). In the treatment of ectopic pregnancy neither the single-dose MTX application nor the salpingectomy had any permanent detrimental effect on the ovarian reserve; serum AMH levels and AFC are unaltered in the long term following single-dose MTX or salpingectomy.
Differentiated thyroid cancer is the second-most frequent tumor among those tumors diagnosed during pregnancy after breast cancer; it also is the most common endocrine malignancy. Pregnancy-associated cancer was defined as a malignancy detected during pregnancy or within 2 years of delivery, but most of the patients with pregnancy-associated cancer were recognized in the postpartum period. The best time for surgery is unclear. Its management is a challenge for both doctors and patients. Enlargement of the thyroid gland in pregnancy is usually a physiological change related to pregnancy, but even if it is rare, it can be due to thyroid malignancy. We report a case of 31-year-old female diagnosed with thyroid papillary cancer during pregnancy with no symptoms except for a lump on her neck. For this reason, the examination of the thyroid gland and the examination of neck lymph nodes should be routinely performed on all pregnant women.
Bu vaka sunumunun amacı erken gebelik haftasında saptanan fetal megasistis ve artmış nukal translusensi ile birliktelik gösteren trizomi 18 olgusunu sunmaktır. Olgu: Hastanın birinci trimester ultrasonografik taramasında fetal longitudinal mesane çapı 19mm, nukal translusensi ise 5 mm olarak ölçüldü. Ductus venozus doppler incelemesinde patolojik ters "a" dalgası tespit edildi. Hastaya 16. gebelik haftasında amniosentez yapıldı. Fetal karyotipleme sonucu trizomi 18 olarak saptandı. Gebelik ailenin de isteğiyle sonlandırıldı. Sonuç: Fetal megasistis ve artmış nukal translusensinin kromozom anomalileri ile birliktelik olasılığı yüksek olduğundan fetal karyotip tayini yapılması gerekliliğini belirtmek istedik. Anahtar kelimeler: megasistis; trizomi 18; nukal kalınlık ölçümü ABSTRACT Object: The purpose of this case report is to present a case of trisomy 18 diagnosed prenatally in early gestation due to ultrasonographic fındings of megacystis and increased nuchal translucency. Case: In the patient's first trimester ultrasound scan, fetal longitudinal bladder diameter was 19 mm and the nuchal translucency was 5 mm. Aditionally on ductus venosus doppler study there was pathologic inverted 'a' wave. At 16th week of gestation amniocentesis was performed. The result of fetal karyotyping was Trisomy 18. Pregnancy was terminated with the approval of the family. Conclusion: We want to emphasize the necessity of fetal karyotyping in cases with increased nuchal translucency accompanying fetal megacystis since probability of chromosomal abnormalities is high.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.